SCHEMBL5787643

SCHEMBL5787643

O=C(Cc1ccnc(Br)c1)c1ccc(F)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
VNN1 O95497 3/20 0.38
NAMPT P43490 1/20 0.37
KDM1A O60341 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
KCNQ3 O43525 2/20 0.36
KCNQ2 O43526 2/20 0.36
KCNQ5 Q9NR82 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
CTNNB1 P35222 1/20 0.36
WNT3A P56704 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5790783 0.89 PIK3CA (0.45) KDM1AHDAC1HDAC6KCNQ3KCNQ2
SCHEMBL4474830 0.85 RAB9A (0.50) NAMPTKDM1AHDAC1HDAC6CTNNB1
SCHEMBL5353997 0.80 NAMPT (0.51) CES2CES1VNN1NAMPTHDAC1
SCHEMBL14143222 0.79 MAPT (0.44) CES1CTNNB1WNT3AGABRPGABRD
SCHEMBL5789404 0.79 ERCC5 (0.46) VNN1KCNQ3KCNQ2KCNQ5PIK3CA
SCHEMBL6643878 0.77 LMNA (0.43) RAB9A
SCHEMBL22589329 0.74 CES2 (0.40) CES2CES1KDM1AHDAC1HDAC6
SCHEMBL22075469 0.74 VNN1 (0.38) CES2CES1VNN1KCNQ3KCNQ2
SCHEMBL3618613 0.74 LOXL2 (0.45) HDAC1HDAC6KCNQ2GABRPGABRD
SCHEMBL1515798 0.73 MAPT (0.61) CES2CES1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1543003-B1 IMIDAZO¬1,2-A|PYRIDINES SMITHKLINE BEECHAM CORP (US) 2006-05-17 EP disclosed
US-20050245520-A1 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors DODIC NERINA 2005-11-03 US disclosed
US-20050234029-A1 Compounds DODIC NERINA 2005-10-20 US disclosed
EP-1543003-A2 IMIDAZO[1,2-A]PYRIDINES SMITHKLINE BEECHAM CORPORATION (US) 2005-06-22 EP disclosed
WO-2004013138-A2 IMIDAZO`1,2-A!PYRIDINES SMITHKLINE BEECHAM CORPORATION (US) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245520-A1 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors SMAD2, SMAD3, ALK CES2 4667/4885CES1 3686/4885VNN1 4098/4885
US-20050234029-A1 Compounds SMAD3, SMAD2, ACVR1 CES2 4581/4885CES1 4089/4885VNN1 4473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.